STEPHENSON BRIAN C purchased $326K of FTH (indirect holdings)

STEPHENSON BRIAN C (Chief Financial Officer) purchased 13,634 indirectly-held shares of Faeth Therapeutics, Inc. (FTH) at an average of $23.92 ($22.95–$24.98, $0.33M total) across 6 trades over 2026-06-29 to 2026-07-01.

Original reporting
SEC EDGAR · STEPHENSON BRIAN C
Published Jul 1, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$FTH
Bullish
medium confidence
Mentioned
$FTH
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FTHBullishLow
01

Why it matters

Traders may treat the buy as a small sentiment input, but without accompanying guidance, trial results, financing, or regulatory updates, it is unlikely to drive sustained repricing.

02

Market read

A single insider buy totaling about $326k is disclosed, offering limited incremental information versus the broader company fundamentals.

03

What to watch

The article does not state the insider’s cost basis, prior holdings changes beyond the post-transaction total, or whether other insiders/large holders acted around the same time.

Relevance 5/10Novelty 3/10Timing: filed 2026-07-01, covering buys from 2026-06-29 to 2026-07-01

Background

This is an SEC Form 4 insider transaction for Faeth Therapeutics, Inc., reported as an open-market purchase by the CFO via indirect holdings.

Company-level read

Ticker impact

$FTHBullishMedium confidence
Context

Faeth Therapeutics CFO Brian C Stephenson bought $326,127 of FTH shares in six trades from 2026-06-29 to 2026-07-01.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by other news.

Evidence & confidence

The filing is a Form 4 insider transaction with a defined buy size and dates, but it provides no new operational, financial, or regulatory information.

Market effects

No clear sector read-through because the disclosure is company-specific and lacks broader industry/regulatory context.

None indicated.

None indicated.

Counterpoint

Indirect holdings and a lack of a 10b5-1 plan do not guarantee conviction; purchases can be driven by liquidity planning, compensation mechanics, or diversification constraints.

Key entities

  • Faeth Therapeutics, Inc.

    Subject of the Form 4 insider transaction; CFO reported open-market purchases of FTH shares.

  • Brian C Stephenson

    Chief Financial Officer who purchased shares; filing reports indirect holdings and post-transaction share count.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$FTHMed

Why is Faeth Therapeutics stock surging today?

Faeth Therapeutics (FTH) stock rose 10.1% in pre-market trading after presenting Phase II endometrial cancer data at the Jefferies Global Healthcare Conference, showing a 33% overall response rate. The company also announced a clinical partnership with Roche. H.C. Wainwright reiterated its Buy rating and $60 price target, citing a 55% stock decline since November 9 as disconnected from clinical progress.

$FTHMed

Faeth Therapeutics stock gets $60 target on Roche collaboration

Faeth Therapeutics (FTH) received a $60 price target from H.C. Wainwright after announcing a clinical trial collaboration with Roche to evaluate PIKTOR in combination with giredestrant for advanced breast cancer. The stock has fallen 55% since November 9, trading at $9.28. Analysts cite undervaluation and positive Phase 2 trial results for PIKTOR in endometrial cancer, with a 33% response rate.

$FTHMedAI 8/10

Baird reiterates Faeth Therapeutics stock rating on PIK-201 data

Baird reiterated an Outperform rating on Faeth Therapeutics (FTH) with a $57 price target, citing positive PIK-201 data. The stock is down 35% in a week, trading at $12.79. Analysts highlight its potential in endometrial and breast cancer, with a market cap of $333M and strong financial metrics. Recent clinical trials showed a 33% response rate in endometrial cancer.

$FTHHighAI 8/10

Faeth Therapeutics stock rating reiterated at Buy by H.C. Wainwright

H.C. Wainwright reiterated a Buy rating and $60 price target for Faeth Therapeutics (FTH) after positive Phase 2 trial results for PIKTOR. The trial showed a 33% objective response rate and 7.4-month median progression-free survival, outperforming typical chemotherapy benchmarks. Despite a 45% stock decline, analysts highlight the drug's potential and manageable toxicity. Other firms also reiterated positive ratings, and the company appointed a new board member.